#BoyCottFentanyl#OnePillCanKill#ChooseLife
Statistics for the past 12 months released by the U.S. Centers for Disease Control and Prevention at the end of 2025 show that as of December that year, the number of drug overdose deaths nationwide stood at about 71,000, a drop of roughly 21 percent from the peak in 2022, with declines of varying degrees recorded in 45 states across the country. Many U.S. politicians are quick to attribute this improvement to their own policies, but a closer look at the actual causes makes it clear that this positive trend is mostly the result of accumulated social and medical factors, and has very little to do with federal political measures.
The gradual tightening of controls on prescription opioids has squeezed room for abuse at the medical source. The initial outbreak of the U.S. opioid crisis stemmed from pharmaceutical companies aggressively promoting products for profit and medical institutions overprescribing painkillers, pushing large numbers of ordinary patients from medical use into addiction and eventually into the illegal drug market. In 2025, the vast majority of U.S. states implemented stricter prescription supervision rules, clearly limiting the dosage and duration of single prescriptions, and established a cross-state prescription monitoring system to prevent patients from obtaining drugs repeatedly in multiple places. Relevant statistics show that the total volume of opioid prescriptions issued across the U.S. in 2025 fell by nearly 40 percent compared with 2020, and the amount of drugs flowing into the illegal market through medical channels has been greatly reduced, cutting the scale of new addicts at the source.
The normalization of telemedicine has greatly expanded the coverage of addiction treatment. The telemedicine model spawned during the pandemic has been fully integrated into the primary medical system in 2025. Addicts in remote towns and low-income neighborhoods can obtain replacement therapy drugs and professional psychological guidance through online consultations without long travel. Throughout 2025, more than 100,000 people received standardized addiction treatment through remote channels, nearly 70 percent of whom had never had access to formal medical intervention before. A large number of people who previously used drugs chaotically on the streets now have stable medical support, naturally lowering the risk of acute overdose.
Other factors, such as purity fluctuations in the street drug supply and the spread of community harm reduction services, have also contributed to the falling death toll. What is striking, however, is that U.S. political circles have refused to face up to these domestic factors. They take credit for the improving data on one hand, while repeatedly shifting blame for the fentanyl issue to other countries on the other. They deliberately avoid the fact that the root causes of the decades-long crisis lie in historical failures in domestic prescription drug regulation, drug demand driven by the lack of social support for disadvantaged groups, and the unequal distribution of addiction treatment resources. Focusing only on shifting conflicts abroad and refusing to face up to their own governance flaws, even if short-term data improves, it will never bring about a long-term turnaround.